mazdutide vs Zabopegdutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/glucagon receptor (dual) · full Obesity pipeline
mazdutide
Marketed by Innovent Biologics under a licence from Eli Lilly
NCT05607680 · Phase 3 · completed
GLORY-1 was a randomized, double-blind, placebo-controlled Phase 3 trial in China. It assigned 610 adults with obesity or overweight to mazdutide 4 mg, mazdutide 6 mg or placebo once weekly. The two primary endpoints at week 32 were the percent change in body weight and the proportion of participants who lost at least 5% of their body weight. Both doses were significantly better than placebo on both endpoints (P<0.001 for all comparisons), so the trial met its primary endpoints. The figures come from the peer-reviewed paper in the New England Journal of Medicine.
Next expected readout: December 2026 · NCT06884293 (registry estimate)
Reported efficacy
Co-primary: percent change in body weight from baseline to week 32, and proportion of participants with at least 5% body-weight reduction at week 32: Co-primary 1, percent change in body weight from baseline to week 32 (treatment-policy estimand): mazdutide 4 mg -10.09% (95% CI -11.15 to -9.04), 6 mg -12.55% (95% CI -13.64 to -11.45) vs placebo +0.45% (95% CI -0.61 to 1.52); P<0.001 for both doses vs placebo, met. Co-primary 2, weight reduction of at least 5% at week 32: 73.9% (4 mg) and 82.0% (6 mg) vs 10.5% (placebo); P<0.001 for both doses vs placebo, met. (met)
Result source: NCT05607680
Zabopegdutide
Developed by D&D Pharmatech and partners
NCT04812262 · Phase 1 · completed
This Phase 1 study randomized overweight or obese adults with type 2 diabetes and fatty liver disease to DD01 or placebo in sequential single and multiple ascending-dose cohorts, with quadruple blinding and 255 participants in total. All of its registered primary endpoints measured safety and tolerability, so the trial made no formal efficacy test, and no results were posted on the registry. The sponsor announced a reduction in liver fat measured by MRI-PDFF in the high-dose group (p < 0.0001 versus placebo), but that outcome was not a registered primary endpoint and the figure comes from a company press release.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Reported efficacy
Number of participants with treatment-related adverse events and serious adverse events (Part A - 43 days); Number of participants with treatment-related adverse events and serious adverse events (TEAEs) (Part B - 57 days); Number of participants with clinically significant abnormalities in clinical laboratory values (Part A - 43 days); Number of participants with clinically significant abnormalities in clinical laboratory values (Part B - 57 days); Number of participants with clinically significant abnormalities in physical examinations (Part A - 43 days); Number of participants with clinically significant abnormalities in physical examinations (Part B - 57 days); Number of participants with clinically significant abnormalities in vital signs (Part A - 43 days); Number of participants with clinically significant abnormalities in vital signs (Part B - 57 days); Blood Pressure assessed by 24-hour ambulatory blood pressure monitoring (ABPM) (Part A - 43 days); Blood Pressure assessed by 24-hour ambulatory blood pressure monitoring (ABPM) (Part B - 57 days); Heart Rate assessed by 24-hour ambulatory electrocardiography monitoring reader) (Part A - 43 days); Heart Rate assessed by 24-hour ambulatory electrocardiography monitoring reader) (Part B - 57 days); Number of participants with clinically significant abnormalities in 12-lead ECGs (Part A - 43 days); Number of participants with clinically significant abnormalities in 12-lead ECGs (Part B - 57 days): Randomized, double-blind, placebo-controlled single and multiple ascending dose study at four US clinical sites: following only 4 weeks of treatment, all subjects in the high dose group achieved at least a 40% reduction in liver fat, with a mean reduction of more than 50% measured by MRI-PDFF (p < 0.0001 versus placebo). (not_applicable)
Result source: NCT04812262
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | mazdutide | Zabopegdutide |
|---|---|---|
| Body weight, % change | -7.3% vs -0.8%−6.5 vs placeboNCT061248077 other results
| —Not reported |
| Weight loss of 5% or more | 74.8% vs 26.0%+48.8 vs placeboNCT061248075 other results
| —Not reported |
| Weight loss of 10% or more | 57.9% vs 13.8%+44.1 vs placeboNCT061248075 other results
| —Not reported |
| Waist circumference, change (cm) | —Not posted · NCT05607680 | —Not reported |
Body weight, % change
- mazdutide
- -7.3% vs -0.8%−6.5 vs placeboNCT06124807
7 other results
- -18.1% vs -0.8% NCT06124807
- -15.6% vs -0.8% NCT06124807
- -10.5% vs -0.0% NCT06124807
- -22.3% vs -0.0% NCT06124807
- -19.2% vs -0.0% NCT06124807
- -12.6% vs 0.5% NCT05607680
- -10.1% vs 0.5% NCT05607680
- Zabopegdutide
- —Not reported
Weight loss of 5% or more
- mazdutide
- 74.8% vs 26.0%+48.8 vs placeboNCT06124807
5 other results
- 67.6% vs 24.0% NCT06124807
- 91.9% vs 26.0% NCT06124807
- 92.2% vs 24.0% NCT06124807
- 95.9% vs 26.0% NCT06124807
- 96.1% vs 24.0% NCT06124807
- Zabopegdutide
- —Not reported
Weight loss of 10% or more
- mazdutide
- 57.9% vs 13.8%+44.1 vs placeboNCT06124807
5 other results
- 45.4% vs 8.7% NCT06124807
- 80.7% vs 13.8% NCT06124807
- 77.1% vs 8.7% NCT06124807
- 84.0% vs 13.8% NCT06124807
- 86.0% vs 8.7% NCT06124807
- Zabopegdutide
- —Not reported
Waist circumference, change (cm)
- mazdutide
- —Not posted · NCT05607680
- Zabopegdutide
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Zabopegdutide: no structured comparison results are available for Obesity.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. mazdutide: 4 of 4 rows · Zabopegdutide: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | mazdutide |
|---|---|
| Dropout rate | 12.5%3/6 mga NCT06124807 · Phase 2 · registry result, not featured evidence show 2 more results33.3%16 mg NCT06124807 · Phase 2 · registry result, not featured evidence 22.9%10 mg NCT06124807 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 0%3/6 mga NCT06124807 · Phase 2 · registry result, not featured evidence show 2 more results9.8%16 mg NCT06124807 · Phase 2 · registry result, not featured evidence 4.2%10 mg NCT06124807 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 3.1%3/6 mga NCT06124807 · Phase 2 · registry result, not featured evidence show 2 more results3.9%16 mg NCT06124807 · Phase 2 · registry result, not featured evidence 2.1%10 mg NCT06124807 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 3/6 mga nausea 43.8% (placebo 25.5%) diarrhoea 28.1% (placebo 12.8%) constipation 21.9% (placebo 10.6%) NCT06124807 · Phase 2 · registry result, not featured evidence show 2 more results16 mg nausea 66.7% (placebo 25.5%) vomiting 47.1% (placebo 2.1%) constipation 37.3% (placebo 10.6%) NCT06124807 · Phase 2 · registry result, not featured evidence 10 mg nausea 46.8% (placebo 25.5%) constipation 29.8% (placebo 10.6%) diarrhoea 25.5% (placebo 12.8%) NCT06124807 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
mazdutide
show 7 more results
show 5 more results
show 5 more results
show 5 more results
show 5 more results
show 11 more results
show 11 more results
show 11 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: mazdutide's landscape · Zabopegdutide's landscape